| Active substance | bulevirtide |
| Holder | Gilead Sciences Belgium B.V. |
| Status | Running |
| Indication | for the treatment of chronic hepatitis delta virus (HDV) infection in plasma (or serum) HDVRNA positive adult patients with compensated liver disease |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 04/04/2023 |